SCHEMBL12608409

SCHEMBL12608409

CCN(C)CCNC(C)(C)c1ccccc1OC

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.35
AOC3 Q16853 1/20 0.35
BCHE P06276 2/20 0.34
ACHE P22303 2/20 0.34
HTR7 P34969 1/20 0.34
ATM Q13315 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12565778 0.85 ALDH1A1 (0.38) CHRM2MEN1KMT2AALDH1A1AOC3
SCHEMBL12608085 0.79 CHRNB2 (0.38)
SCHEMBL12608049 0.78 MEN1 (0.40) CHRM2MEN1KMT2ABCHEACHE
SCHEMBL12608093 0.78 CHRM2 (0.39) CHRM2MEN1KMT2AALDH1A1LMNA
SCHEMBL1133388 0.77 GAA (0.42) CHRM2MEN1KMT2AALDH1A1BCHE
SCHEMBL1132381 0.77 TAAR1 (0.43) CHRM2MEN1KMT2AALDH1A1BCHE
SCHEMBL12608124 0.77 HPGD (0.32) CHRM2KMT2A
SCHEMBL12609266 0.75 ALDH1A1 (0.39) CHRM2MEN1KMT2AALDH1A1LMNA
SCHEMBL12608619 0.75 CHRM2 (0.37) CHRM2MEN1KMT2AALDH1A1LMNA
SCHEMBL12609255 0.75 KCNN4 (0.40) CHRM2MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 CHRM2 3997/4885MEN1 3582/4885KMT2A 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.